Biosyngen Announces FDA Fast Track Designation For BST02 In Treatment Of Liver Cancer

SINGAPORE, Feb. 1, 2024 /PRNewswire/ -- Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of all types of...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials